februari
dupont nutrit bioscienc appear make strateg sens
merg dupont appear make strateg sens creat new
ingredi pf sale complementari technolog across specialti
 probiot enzym well bulk ingredi emulsifi iff-dupont
becom one-stop-shop sector
yet time wors contempl deal
frutarom integr challeng say least still progress time
wors contempl addit deal given sceptic
iff synergi target consid long pain integr journey ahead expect
materi ep dilut first four year deal
 divers opaqu busi mani question good
dupont bs asset two complementari busi gener meaning synergi
integr two diversifi busi without destroy valu
comfort dupont dress bride exit
parti rate under-perform
stock recov sinc announc deal dec larg driven short-term
posit solid wide expect ii support major sharehold
winder set disappoint year materi risk three-way integr
frut adj ep consensu maintain under-perform
question manag
enclos question manag could address elucid deal
exan bnpp estim thomson reuter consensu list currenc dividend reinvest
date time london time invest recommend finalis may differ date time broad dissemin
websit appendix analyst certif import disclosur non-u research analyst disclosur
price feb target price
price yearli average dec dec
share year end basic
average share dilut excl treasuri stock
 rel usa
liabil commit
chang wcr
increas decreas net financi debt
rel usa usd
intang per share adjust capit gains/loss except restructur charg capit ebita also adjust impair intang
 ebita adjust financi result/tax adjust list currenc ith div reinvest
merg dupont nutrit bioscienc
dupont nutrit bioscienc
strateg benefit
question good dupont nutrit bioscienc
question execut two deal
question realist synergi target
parti reiter under-perform
question manag
invest case valuat risk
compani profil financi highlight
marriag like mushroom notic late good bad
merg dupont nutrit bioscienc appear make
combin dupont creat new specialti ingredi
highli complementari technolog across specialti flavor probiot bulk
ingredi emulsifi pf sale iff-dupont becom
one-stop-shop sector
figur dupont strateg benefit
benefit
becom sector
diminish market focu frutarom
creat largest diversifi ingredi compani
becom even bigger givaudan kerri largest
estim year
frutarom pf sale
yet time wors contempl deal
frutarom integr still progress challeng say least
believ time wors contempl addit
deal past preced sector iff limit track record suggest
three-way frutarom dupont integr long pain
journey given sceptic iff synergi target like disrupt sale
dis-synergi deal anticip materi ep dilut come four
unit shown
 opaqu busi within dupont mani question
deal good dupont bs asset seamlessli integr two
diversifi adjac busi realist bold synergi target
extent dupont dress bride exit
hope abl enlighten us addit
question present report build confid deal
figur dupont key question mark
good dupont nutrit bioscienc
seamlessli execut yet anoth monument
sale synergi achiev
realist cost synergi
sustain dupont bs high margin
dupont gener well-perceiv direct peer group
exposur financi track record suggest mix busi
preced suggest even best face challeng even much
smaller integr project integr busi
sale loss look like sale synergi like take
look challeng given materi raw materi overlap differ
product set
risk window-dress dupont lower growth need
parti rate under-perform
stock recov sinc announc deal dec larg driven
short-term posit solid result wide expect ii buy
pressur major sharehold winder yet set anoth
disappoint year materi risk three-way integr adj ep
consensu maintain under-perform rate
figur consensu
question manag
enclos question manag could address elucid
give confid bulk integr done
year preced major transform process appear
long-term incent polici chang focu de-lever vs
econom profit decis re-lev balanc sheet impact execut
make better partner dupont other
merg dupont nutrit
merg dupont creat new global leader ingredi
highlight deal
surpris market last christma announc intent
merg dupont creat new compani
key financi term deal base iff share price dec shown
dupont sharehold new compani
sharehold ratio fix part deal dupont receiv
one-tim cash payment complet
figur offer dupont
compani exan bnp pariba estim base iff share price dec
offer reflect multipl dupont bs ebitda includ full
run-rat cost synergi estim
figur offer ebitda dupont
compani exan bnp pariba estim base share price dec synergi
expect realis year
agreement unanim approv board director
transact expect close end subject customari
close condit compani state confer call regulatori issu
expect due limit overlap two compani long period
deal closur driven carv project dupont end includ
deal requir major approv sharehold sharehold
vote requir dupont side largest sharehold winder own
agre vote favour deal
iff sharehold vote like take place cours summer
follow close deal andrea fibig current chairman ceo
lead pro-forma compani
new compani board director consist director
current director dupont director appointe
director compani dupont execut chairman ed breen
join board serv lead independ director start june
deal termin requir pay termin fee
dupont sharehold approv deal must also reimburs
dupont transact expens
dupont state rational deal elabor later
report creat new global giant ingredi strong product
develop capabl strong leadership posit across multipl ingredi
ceo andrea fibig comment
combin pivot moment journey lead
industri invalu innov creativ partner custom togeth
creat lead ingredi solut provid broader set
capabl meet custom evolv need
highli complementari portfolio global scale lead
posit key growth categori capit posit market trend drive
strong profit growth sharehold creat opportun
dupont presid matthia heinzel comment
team excit opportun build new compani creat
new world-class leader expertis togeth best posit us
address custom need ultim redefin industri
short video explain deal rational
confer call deal reveal three highli motiv
bidder seek partner believ other dsm kerri
dupont state partner choic shown
excerpt post-deal confer call
team unanim bug mark pleas deal
think machin kind stay way go
way focu custom team get along obvious
know industri cultur fit becom realli
import us big reason
question valu creation potenti dupont continu
believ kerri would offer less execut valuat risk perhap
easier execut rmt us partner limit technolog overlap
set merg dupont creat new specialti ingredi
subject sharehold vote later year
dupont nutrit bioscienc
dupont diversifi ingredi player
dupont nutrit bioscienc diversifi ingredi busi headquart
copenhagen denmark becam part dupont follow public take-over
danisco list denmark sinc busi grown
diversifi number acquisit includ pharma food
microbi control health nutrit busi current gener sale
ebitda margin
busi broad exposur rang probiot cultur
enzym textur sweeten protein solut end-market also
broad rang food beverag dietari supplement pharma home
person care bioethanol anim feed
figur dupont organis around platform
polym seaweed-
base excipi
show overview bs sale exposur sub-platform
sale sub-platform
sale geographi
dupont exan bnp pariba estim food beverag bioscienc note geograph sale split includ
busi report non-cor
figur dupont divers exposur across food beverag pharma
busi undergon chang past year perhap
prepar exit
sinc june former nutrit food ingredi industri
bioscienc industri enzym oper segment repackag platform
describ
number non-strateg area biomateri clean technolog
shift dupont non-cor segment
margin dilut natur color busi exit ddw juli
former presid industri bioscienc william feeheri left compani
entir busi leadership matthia heinzel former
presid nutrit
overview dupont bs key financi courtesi chemic team
dupont bs disclosur rel opaqu one segment within
sluggish top line growth
 bs organ growth sluggish past year driven volum reason
given includ slowdown probiot enzym esp supplement ethanol
also report chr hansen novozym suppli chain disrupt sweeten
de-stock protein
dupont expect organ growth line mid-term
target per investor day grow iff-dupont
merger confer call compani state adjust year asia
probiot would back growth part driven capac
expans hope issu observ temporari
dupont bs ebitda margin quit attract much higher
broader ingredi peer driven mix margin differ wide product
area bioscienc peer chr hansen novozym print ebitda
margin wherea peer food beverag margin mid-teen
dupont bs manag believ segment margin top
quartil rel peer
chemic team sub-segment estim shown food beverag
largest busi area lowest margin
figur dupont estim platform
health
bioscienc microbi control
dupont diversifi busi number attract exposur look
complementari
strateg benefit
dupont appear make strateg sens
might stretch middl integr frutarom see
main benefit merg dupont
figur dupont strateg benefit
benefit
becom sector
diminish market focu frutarom
creat largest diversifi ingredi compani
strong market posit
becom even bigger givaudan kerri largest
estim year
frutarom pf sale
increas breadth market leadership
evolv busi model focus flavor fragranc
player becom diversifi player mani adjac exposur
pursuit diversif one key reason paid high price
ebitda frutarom merg dupont would take iff-frutarom new
level technolog exposur market leadership across multipl categori
figur iff-frutarom dupont highli complementari
emulsifi soy protein other note dupont exposur
flavor exit firmenich recent sold natur color
busi ddw discuss earlier section
figur dupont divers portfolio complementari
divers exposur advantag custom increasingli ask
favour supplier broader multi-ingredi holist approach
innov due
rise local region food servic privat label custom need help
multipl ingredi
fragment consum trend well
gener trend custom cut supplier list
dupont provid two exampl shown complementar
offer togeth iff-dupont account larger share custom
figur dupont bs ingredi complementari
would achiev ambit becom
combin dupont nutrit bioscienc unit would creat pf group
sale make largest player sector
figur pro-forma group would new specialti ingredi
believ achiev manag would particularli proud
note acquir frutarom describ drive signific progress toward
figur size matter buy frutarom enabl signific progress
merg would also enabl compani meet long-held ambit
overtak closest peer givaudan sale shown
figur size matter merg make larger peer
size appear matter corpor world dupont chairman ed breen
state deal confer call
peopl love work global leader know go get
go top heat pretti darn good
feel salesperson pretti motiv thing like oh
gosh look tool go tool bag
larger revenu base also impli larger absolut spend pf
cost estim
figur iff-dupont largest spend sector
compani exan bnp pariba estim latest avail fy data compani
valu creation synergi
estim run-rat cost synergi year integr much
like frutarom integr benefit larg come
procur ii streamlin corpor overhead cost iii manufactur
effici shown
figur dupont expect materi cost sale synergi
dupont deal present
addit revenu synergi expect year
gener addit ebitda margin
opportun mask issu frutarom
asid anoth potenti advantag merg giant like
would diffus market attent away under-perform frutarom busi
frutarom would account pf sale current one-third
manag continu believ busi time return mid-
singl digit growth continu view unlik highlight indigest
downgrad under-perform
figur frutarom grown mid-singl digit rate sinc took
alreadi propos new segment structur involv
ad frutarom busi legaci iff tast divis anoth
restat back anoth transform deal could muddi
water
figur redefin busi unit new report
iff-dupont combin would line iff strategi diversifi
adjac make strateg sens poor time contempl
monument deal may suggest addit motiv
mani question still need answer sharehold unlik
forgiv execut challeng
iff plan merg dupont seem make strateg sens
hope time creat valu deal yet given sheer
size transact largest histori sector frutarom
believ fair detail look potenti risk ahead
summaris risk describ detail next section
figur dupont key question mark
good dupont nutrit bioscienc
seamlessli execut yet anoth monument
sale synergi achiev
realist cost synergi
sustain dupont bs high margin
dupont gener well-perceiv direct peer group exposur
financi track record suggest mix busi
preced suggest even best face challeng even much
smaller integr project integr busi
sale loss look like sale synergi like take much
look challeng given materi raw materi overlap differ
product set
risk window-dress dupont lower growth need
question good dupont nutrit
attract dupont mean iff portfolio
anecdot evid broader industri suggest dupont gener
well perceiv attract margin suggest value-ad specialti
ingredi busi howev portfolio quit mix high-end ip rich
technolog probiot enzym well bulk commodity-lik exposur
show list dupont bs key peer dupont competitor
sourc last avail add novozym struggl
understand includ main conclus
 bs peer aggreg trade lower valuat iff suggest
eye market nutrit bioscienc dilut term portfolio
figur peer trade higher valuat dupont
point clarif
note dupont time time associ peer
see investor day present perhap given high valuat
believ fs dupont real competitor ground note
dupont would complementari describ
rational merger
figur view fs real peer dupont
dupont bs exposur natur local region custom
believ dilut iff posit metric estim
sale multin fair amount non-natur exposur
figur dupont less favour custom mix
compani exan bnp pariba estim note group level figur
dupont also expos commodity-link end market anim health
ethanol end market cyclic offer volatil iff core
figur dupont cyclic exposur
estim sale end market
look financi perform estim dupont deliv
organ growth averag past year signific volatil
show say estim histor account rather confus
restat multipl time follow creation dowdupont organ
growth averag period note
under-perform target peer recent year
figur under-perform broader sector growth
compani exan bnp pariba estim histor figur take weight averag
disclosur ib
past year especi pain dupont signific volume-
figur dupont bs organ growth deterior recent quarter
dupont under-perform organ growth
dupont bs volum challeng yoy
last result especi surpris featur organ growth
volum despit easi comp upbeat confer call mid-dec
ebitda consensu estim exactli investor expect
pay high multipl defens ingredi exposur
figur dupont disappoint
one bright spot dupont profit margin increas significantli
past year like driven effici mix scope chang
figur dupont attract margin
dupont attract ebitda margin
ebitda margin improv significantli vs
dupont diversifi busi mix financi track record
question execut two
deal
say alway seem imposs done manag
integr
one main concern deal time midst integr
frutarom sale ad sale frutarom integr
far challeng say least plan layer
addit worth sale doubl revenu base manag
seamlessli carri larg complex integr project
figur much soon plan integr two busi
busi transform programm integr project highli
disrupt organis even best oper industri face
challeng provid preced
givaudan underw two transform event mid late portfolio
rationalis programm commod ingredi exit
year ii acquisit quest
quest top compani direct peer givaudan estim
market share compani under-perform sector given poor
manag parent compani ici major suppli chain challeng
couldnt locat raw materi led custom loss
present organ sale histori givaudan note slight slow patch
mid late confirm compani mani peer
believ quest integr mani challeng result market share
figur givaudan softer patch late
adj rationalis
one major cautionari tale sector firmenich acquisit
danisco non-cor flavor busi firmenich player
would reason expect run busi better danisco
rel eas compani estim lost half ye half acquir
sale due poor integr effort competit peer
symris creat merger two competitor locat liter side-
by-sid holzminden germani privat equiti help acceler
integr ahead pf compani ipo employe still refer period
disrupt given cultur differ two compani note two
compani neighbour rural germani
dupont acquir danisco anecdot evid broader sector suggest
major challeng follow take-over part due major cultur differ
two organis awar mani former danisco employe
left work ingredi compani aak chr hansen novozym
present comment post glassdoor global review site compani
cours on-line review must taken pinch salt peopl
like go way post neg rather posit review provid
first hand evid integr far seamless
figur glassdoor review dupont danisco
kerri underw extens busi transform programm build
current oper model project
implement exercis last year arguabl still fulli
complet bed mani bolt-on acquisit creat today tast
nutrit platform kerri growth challeng emea toward end
transform project mid compani admit hindsight
distract inward look transform process
figur kerri tast nutrit emea softer patch mid
adj rationalis
compani exan bnp pariba estim note show europ reflect
compani chang report
iff-frutarom-dupont fare
preced mainli involv core busi transform
adjac mind seem fair wonder fare attempt
nobodi done simultan execut two major integr
project outsid area core compet
pertin question note perceiv market much
volatil financi oper vs closest european peer
number oper issu highlight year may attribut bad
luck recur natur except event rais question
number issu disclos past year led major earn
miss shown
chines flavor site close week given odour issu reduc margin
figur multipl issu recent year
organ sale due custom destock custom rationalis issu china
chines govern request reloc ingredi site zhejiang
manufactur issu custom bankruptci fda mandat product recal litig loss
plant reloc india lab closur asset write-off taiwan
chines govern chang zone guangzhou scent plant destock flavor
potenti re-zon guangzhou flavour plant
report peer sharehold lawsuit follow frutarom deal
frutarom integr unfortun done littl redeem iff imag
poor unlucki oper last month challeng say
least growth target rang mid-singl digit complianc
issu briberi russia ukrain report
figur frutarom grown mid-singl digit rate sinc took
mind sure iff integr seamless
preced suggest even best get disrupt much smaller scale
transform integr project feel optimist expect seamless integr
iff-dupont
question realist synergi
two complementari busi materi synergi
iff-dupont expect gener materi cost sale synergi
merger impress achiev realist target
figur dupont target materi sale cost synergi
sale synergi come
dupont target sale synergi year bring
increment ebitda main driver cross-sel
leverag compani custom base sound good theori
question achiev
easi win top-lin
look preced sector one easiest way global acquir
extract sale synergi acquir smaller player limit geograph
footprint custom base roll target technolog use buyer
larger distribut platform custom relationship exampl includ
kerri buy us-bas redarrow good stand local custom
access outsid us redarrow asia
buy luca meyer givaudan acquir solianc enabl
small cosmet ingredi busi get larger custom struggl
penetr
differ case dupont sizeabl well-
respect leader field broad global custom base mean
potenti sale synergi less obviou less easi achiev
dis-synergi custom concentr
two compani limit overlap term product base see risk
sale dis-synergi especi multi-national custom estim
 sale
breakdown raw materi cost base liquid deterg fragranc
enzym alon account materi share raw materi cost base
combin would unilev henkel comfort entrust singl supplier
larg share input cost base nobodi els offer combo
would custom realli take risk lock one supplier
figur raw materi cost base liquid deterg
differ sale model
much legaci iff busi base respond highli specif single-
ingredi brief receiv presenc variou core list core list
prefer supplier list enabl player attend product brief host
multi-national custom busi model therefor primarili pull rather
push custom initi request
frutarom contrast highli aggress push model marri two
diverg busi approach like remain challeng task
help wonder intend layer dupont top gener
sale synergi offer integr solut nestl brief specif
call strawberri flavour new chocol bar abl sell
protein well would even allow term condit core
list peer paid materi sum cash
nobodi els offer protein flavour would nestl realli want take
risk lock one supplier
one benefit combin dupont two compani
limit overlap one must care think complementar
alway equal provid one illustr exampl relat
laundri care
state new compani sort one-stop-shop laundri deterg
custom abl offer multipl ingredi go given formul
figur dupont target laundri care custom among other
excit concept doubt dupont bs enzym
custom may adopt iff fragranc formul howev also see scope
ingredi cannibalis
dupont report investor day laundri care solut
figur dupont offer microbi solut control laundri malodour
separ malodour technolog fragranc laundri care applic
extent iff malodour technolog compet dupont enzymat
solut malodour technolog effect wouldnt deterg
requir less fragranc sometim ad mask bad odour
pertin question given mani custom seek reduc cost
note novozym also roll new malodour reduc enzym
previous state expect enzym cost neutral custom
someth els remov formul comment ander
lund evp household novozym
analyst deterg produc adjust shelf price adopt new
ander lund think expect sale price chang think everi
time includ new claim chang formul way
basic entir formul play least experi
seen tri balanc cost mean someth go
someth come case fresh platform come
risk price concess
idea bundl two ingredi help custom save time
cut supplier risk approach result valu
destruct form price concess manag appropri
give two exampl
chr hansen three divis food cultur enzym ii nutrit
iii natur color first two divis microbi busi
share backbon color howev differ busi term
custom base sale process cost structur carv
period under-perform
explain carve-out chr hansen ceo state
natur color reach organ growth exclud carmin price effect
natur color expect neg affect percentag point
loss major custom satisfi perform
wish better
address recent perform also get closer color
custom addit ensur stronger focu execut relev
color segment like beverag confectionari ice cream prepar food
today announc establish dedic sale organ integr
sale applic organ global sale
new organ ensur agil decision-mak process fulli
integr valu chain natur color support ambit ensur solid
growth natur color establish fulli integr color organ creat
transpar understand color busi also support
long-term margin growth toward target mid-teen ebit margin
understand chr hansen histor fair amount
cross-sel dairi cultur fc segment natur color may
sold togeth custom make pink strawberri yogurt yet
technolog never integr sold custom non-integr
bundl issu bundl absenc addit technic value-
add leav room price negoti much like multi-buy offer
retail meant chr hansen color margin lower-tech solut
often sacrif price negoti custom
busi therefor carv separ sale forc manag
team respons
anoth exampl fail bundl exercis involv monsanto smartstax corn
seed launch late noughti innov contain eight differ gene
vs prior altern promis farmer comprehens all-in-on
yield protect weed insect
farmer howev fail see valu high-pric seed monsanto
ultim slash price drive demand word monsanto
unsuccess preserv valu sotp
guid run-rat cost synergi year
save come
easi win cost save
dupont professionally-run effici organis high
margin unlik low hang fruit come cost save
merger thu differ past larg deal sector involv
acquisit under-perform mis-manag
figur dupont alreadi high margin
raw materi overlap
dupont expect half cost synergi come procur save
come given limit overlap across two portfolio
legaci tradit busi extrem divers raw materi
base approx input none individu amount
singl digit total input cost base
dupont nutrit bioscienc hand report follow key raw
materi parent compani
terephthal acid gelatin glycol cellulos process grain includ dextros
sugar yeast vanadium use catalyst
limit overlap raw materi project save amount
cost synergi come
manufactur synergi achiev
similarli manufactur effici come
overlap anybodi visit chr hansen copenhagen site food cultur
enzym novozym enzym site awar highli specif
combin say flavour site note chr hansen natur color
busi complet separ food cultur enzym independ
iff-dupont sale cost synergi target impress struggl
understand achiev
addit question includ follow
sustain bs attract margin
dupont report ebitda margin increas
past year driven remark result current high
margin sustain gain comfort
dupont
underinvest busi dress bride prepar exit
figur dupont significantli increas margin past year
chang ebitda margin bp vs
addit strand cost
dupont includ much corpor expens divis
financi updat june note group still corpor
expens
cost carve-out-typ expens includ
deal depress profit year worth carv project
horizon note main reason long delay close deal could
expect addit expens aris
exactli dupont bs price strategi
anecdot evid dupont peer suggest dupont price much lower
competitor cultur enzym unusu strategi view true
given rel consolid natur market way may serv
explain pain felt chr hansen recent quarter
rational approach would happen volum narrow
price gap vs peer manag
present mani question fact later report
materi execut risk horizon pf financi like
strateg merit question execut asid next outlin financi
implic yet integr dupont estim deal
still subject sharehold approv
key financi term offer base iff share price dec shown
dupont sharehold new compani
sharehold ratio fix also pay cash
figur offer dupont
compani exan bnp pariba estim base iff share price dec
offer reflect multipl dupont bs ebitda includ full
run-rat cost synergi estim
figur offer ebitda dupont
compani exan bnp pariba estim base share price dec synergi
expect realis year
equiti ratio two compani fix dupont bs valuat
fluctuat iff share price show term deal base iff
current share price also account estim pension
guidanc
financi guidanc provid includ
run-rat cost synergi sale synergi year
highlight earlier report
synergi cost
pf net debt adjust ebitda close de-lever
commit maintain invest grade credit rate
present pf estim financi effect deal assum
dupont consolid start per guidanc
cost synergi amount half guidanc achiev
year believ target ambiti outlin earlier report
sale synergi believ take much longer materialis
given heavy-lift requir integr busi believ sale loss
cannibalis like assum pf sale year
reduc outer year
pf financi shown
compani exan bnp pariba estim indic assum integr incl synergi disrupt commenc
pf leverag expect shown
pf implic shown full model avail upon request
deal significantli dilut given multipl paid high interest expens
conserv synergi assumpt recent downgrad dupont
unit shown
lacklustr pf financi driven bearish assumpt synergi
take iff guidanc face valu
assum full cost synergi guid would impli ep accret
assum sale synergi top gener ebitda
less opex reinvest guid would impli ep accret
pro-forma valuat downsid risk upsid
next show sensit tabl iff pf valuat differ target multipl note
pure illustr yet pf dupont
estim deal confirm get sharehold
approv target price stand-alone compani
figur theoret pf valuat differ ev/ebitda multipl
unit shown
upside/ side
assum stock re-rat valuat givaudan ebitda would
impli upsid howev believ highli unlik achiev given
compani patchier track record execut greater earn volatil
stock histor trade discount givaudan two
compani similar exposur pure compani assum pf
busi trade discount givaudan valuat would impli
ebitda upsid
figur histor trade discount givaudan
howev view materi discount vs histori well-deserv account
like lower pf organ growth estim mid-term
frutarom lower qualiti busi
materi execut risk
dent manag credibl given surpris natur stretch deal
stand-alone valuat impli ebitda
assum multipl pf group would impli fair valu
signific earn dilut low materi potenti downsid risk
maintain cautiou stanc deal
parti reiter under-perform
recent re-rat like short-liv reiter under-perform
stock recov follow announc deal dec
believ driven two factor major sharehold winder buy
stock ii short-term market posit result
figur stock bounc back post deal announc
show major sharehold winder purchas sinc announc
deal investor alreadi agre vote favour deal own
share capit
figur winder support stock post deal announc
unit shown
posit
market sentiment improv past quarter confid deliv
mid-singl digit growth givaudan recent upbeat commentari
slowdown anywher serv excit market
figur organ growth set recov materi sluggish
note growth support week
price benefit fade inflat pass-through enter key
custom unilev signal slower environ like
disrupt coronaviru less travel retail less demand perfum
beauti care expect anoth disappoint year notwithstand
disrupt frutarom integr
figur consensu
parti maintain under-perform rate
ep consensu estim maintain under-perform
question manag
cfo rich state would remain focus frutarom integr
balanc sheet de-lever would consid move put
balanc sheet risk chang
long-term incent polici chang focu de-lever vs
econom profit decis re-lev balanc sheet impact execut
similarli recent announc mid-term target top-lin ep
growth longer look valid impact execut compens
make better partner dupont other
expect ep accret deal follow dupont
expect wacc deal
view share price reaction post announc
give confid rmt given preced
forese dispos integr rmt guidelin
earliest combin entiti execut dispos
perceiv main opportun risk relat deal
role matthia heinzel presid nutrit bioscienc play
rational hire extern cfo differ industri
happen frutarom leadership yoni ensur
frutarom employe feel marginalis within big machin
senior leadership team reflect integr busi model
organis technolog area
incentivis sale peopl product end use market
isnt ed breen age join lead independ director
state origin director dupont
board becom vs anticip leav
feel comfort execut capabl given limit
track record larg seemingli volatil oper histori
give confid bulk integr done
year preced major transform process appear
appear rush site consolid phase frutarom
integr done time riski idea
learn frutarom integr might abl
make use merg dupont
believ import global erp platform
budget arriv estim risk
could increas given dupont current go carve-out exercis
mani unknown
forese sale dis-synergi even small initi phase
integr project cross-sel benefit come
assumpt behind synergi guidanc expect
benefit retain long-term
procur synergi come given limit raw materi
gener manufactur synergi technolog exposur
state team speak languag need
produc flavour differ need produc probiot pleas
discuss integr
manag conflict get larger lose agil
offer custom integr multi-ingredi offer note
lot busi oper basi brief
main rational deal appear creat sort one-stop-shop
custom custom get
definit integr solut
current infrastructur place offer integr solut
wont need make materi platform invest peer done
believ better broad rang ingredi
technolog rather focu buy rest emulsifi
explain dupont grown recent
much visibl dupont given bullish
call mid-dec disappoint significantli result
comfort dupont bs project mechan
place get compens project grossli incorrect
growth rate dupont assum cultur enzym
feel may structur slower area see chr hansen
extent dupont bs busi impact churn cannibalis
view three platform within dupont view
segment value-accret
think dupont increas volatil top-lin growth
given exposur cyclic end market ethanol anim health
extent believ dupont bs technolog future-proof
 wont methylcellulos one day replac altern
proport dupont bs product base truli natur
proport dupont bs custom base made multin vs
price work dupont
dupont bs margin evolut impress driven
view sustain work done ensur dupont
dress bride
pleas discuss dupont bs cash flow profil
pf organ growth expect follow integr
target higher pf margin peer believ cap
profit custom tend lower margin high margin
plant-bas theme excit opportun iff-dupont
much sale
riski take much leverag busi environ
unpredict raw materi spike eat cash flow quit
invest case valuat risk
materi risk three-way frutarom dupont integr
adj ep consensu maintain under-perform rate
target price base sotp impli
upsid
upsid risk includ faster progress frutarom dupont
integr project greater expect synergi retent materi uptick
demand rapid declin raw materi price market share gain favour
chang fx especi usd/eur
downsid
downsid risk includ slower progress frutarom dupont
integr project lower expect synergi retent materi slowdown
demand rapid increas raw materi price loss price power increas
competition/market share loss oper issu expens
materi chang fx especi usd/eur
